SHORT COMMUNICATION: Sulindac suppresses tumorigenesis in the Min mouse

1996173 citationsJournal Articlebronze Open Access

Authors

Yasmin Beazer-Barclay · Johns Hopkins University

Daniel B. Levy · University of Wisconsin–Madison

Amy Moser · University of Wisconsin–Madison

William F. Dove

Stanley R. Hamilton · Johns Hopkins Medicine

Bert Vogelstein · Johns Hopkins University

Kenneth W. Kinzler · University of Wisconsin–Madison

Abstract

The Min mouse provides a genetically defined model for inherited and sporadic forms of human colorectal tumorigenesis. To test the suitability of this model for the evaluation and optimization of chemopreventive agents, we examined the effects of sulindac on tumorigenesis in Min mice as this compound can inhibit colorectal tumorigenesis in human familial adenomatous polyposis patients. Treatment of Min mice with sulindac in their drinking water (84 mg/l) or diet (167 and 334 p.p.m.) resulted in a significantly decreased average tumor load. The conservation of sulindac activity in the Min mouse provides an opportunity to explore the mechanism of sulindac suppression as well as to test other potential chemopreventive agents.

Topics & Keywords

Inflammatory mediators and NSAID effects Helicobacter pylori-related gastroenterology studies NF-κB Signaling Pathways

UN Sustainable Development Goals

Clean water and sanitation

Publication Details

Published in: Carcinogenesis

Volume 17, Issue 8, pp. 1757-1760

DOI: 10.1093/carcin/17.8.1757

Field-Weighted Citation Impact: 10.84